Churbz: You don't understand LymPro. You are basing your frustration on the fact Gerald didn't say 95% specificity and 92% sensisitivity with in a multivariant analysis. You've been programmed to have expected this. But it isn't the relevant metric that you think it is.

Lympro has right now the ability to have 90% specificity, and that is what pharma cares about.

By buying Georgetowns tests we do gain some other advantages that help us corner the market.

I know you didn't hear what you think you needed to hear, but what you thought you needed to hear wasn't what your needed to hear. LymPro is "highly statistically significant," that is what you needed to hear! And you heard it!

I think we're right on target.